Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML

Abstract FLT3 mutations occur in approximately 25% of all acute myeloid leukemia (AML) patients. While several FLT3 inhibitors have received FDA approval, their use is currently limited to combination therapies with chemotherapy, as resistance occurs, and efficacy decreases when the inhibitors are u...

Full description

Saved in:
Bibliographic Details
Main Authors: Helene Sieberer, Michela Luciano, Diana Amend, Constantin Blöchl, Anna Eglseer, Alina Steinkellner, Sebastian Rieser, Ancuela Andosch, Philip Steiner, Laura Hummer, Peter W. Krenn, Hieu-Hoa Dang, Christian G. Huber, Fritz Aberger, Theresa Neuper, Jutta Horejs-Hoeck
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Cell Communication and Signaling
Online Access:https://doi.org/10.1186/s12964-025-02046-w
Tags: Add Tag
No Tags, Be the first to tag this record!